Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK T474I |
| Therapy | Pirtobrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK T474I | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with chronic lymphocytic leukemia harboring BTK C481S experienced progressive disease after an initial response on treatment with Jaypirca (pirtobrutinib) and was found to have acquired BTK T474I and lost BTK C481S (PMID: 39048721). | 39048721 |
| BTK T474I | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, two patients with chronic lymphocytic leukemia who previously responded to Jaypirca (pirtobrutinib) treatment were found to have acquired BTK T474I upon disease progression (PMID: 35196427). | 35196427 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35196427) | Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. | Full reference... |
| (39048721) | Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. | Full reference... |